H.C. Wainwright lowered the firm’s price target on iTeos Therapeutics to $44 from $54 and keeps a Buy rating on the shares post the Q2 report.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ITOS:
